The purpose of this booster study is to evaluate the immune persistence in healthy Chinese
subjects primed in study NCT01086423 with GSK Biologicals' Infanrix-IPV+Hib™ (DTPa-IPV/Hib)
vaccine. The study will also evaluate the safety and immune response of these subjects to a
booster dose of Infanrix-Hib™ (DTPa/Hib) and Poliorix™ (IPV) vaccine.
This protocol posting deals with objectives & outcome measures of the booster phase. The
objectives & outcome measures of the primary phase are presented in a separate protocol
posting (NCT number = NCT01086423).